Welcome & Innovation Highlights at OIS@ASRS 2016. Participant: Emmett T. Cunningham Jr., MD, PhD, MPH, Partner – Clarus Powered by: Healthegy For more ophthalmology innovation Visit us at www.ois.net

2. Healthegy Team
Craig Simak
Co-Founder &
Executive Producer
Danielle Silva
Manager, Planning &
Production
Maureen Linnemann
Sponsor Relations
Manager
Tom Salemi
Content Director
Karin Englund
Marketing Team Leader
Joanne Carrillo
Controller
Mario Escamilla
Visual Designer

3. Most Recent OIS Meetings
5th Annual OIS@ASCRS
New Orleans, LA
May 5th, 2016
7th Annual OIS@AAO
Las Vegas, NV
November 12th, 2015

4. Inaugural OIS@ASRS

5. Global Ophthalmic Pharmaceutical Market
Revenues by Indication
MarketSource: Market Scope Estimates; Courtesy Dave Harmon. http://market-scope.com/
9.3
16.5
4.7
6.1
3.1
3.7
3.8
4.2
0
5
10
15
20
25
30
35
2015 2020
$20.9 Bn
$39.5 Bn
Anti-VEGF/Retina
Glaucoma
Dry Eye
All Other

6. Global Ophthalmic Procedures - 2015
Vitrectomies
Laser
Photocoagulation
IVT Injections
Cataract, RLE,
Phakic IOLs
Laser Refractive
Glaucoma Filtering, Shunts, MIGs
Glaucoma Laser
All Other
MarketSource: Market Scope Estimates; Courtesy Dave Harmon. http://market-scope.com/
Retina – 25.7M
24.2M

7. VC Investment By Ophthalmic Indication (1999-2015*)
*2015 figures through October
SOURCE: Strategic Transactions
49
37
21
19
12
14
10 7
14
10
3
4
0
10
20
30
40
50
60
0
100
200
300
400
500
600
700
800
900
1,000
1,100
1,200
NumberofDeals
PrivatePlacements($M)
Dollars ($ Millions)
Number of Deals
RETINA

8. ASRS Leadership and
Honorary Co-Chairs
Tarek S. Hassan, MD
President
Honoary OIS Co-Chair
Mark S. Humayun, MD, PhD
President-Elect
Honorary OIS Co-Chair
Jill F. Blim, MS
Executive Vice President

9. OIS Attendees Over Time
Inaugural
OIS@ASRS
( ~ 28 K ; ~ 4 % )
( ~ 8 K ; ~ 7 % )
( ~ 1.8 K ; ~ 13 % )

10. OIS@ASRS Attendees – 2016 ( ~ 225 )
29%
25%
14%
11%
10%
6%
4%

12. Networking Lunch Host
Vince Anido, Jr, PhD
CEO & Chairman of the Board
Thomas A. Mitro
President and COO Richard J. Rubino
CFO
Casey C. Kopczynski, PhD
CSO

13. The Retina

14. Retina Company Showcase
Moderated By:
Tracy Saxton, PhD
Investment Director
Roche Venture Fund

15. Financing Environment
Introduced By:
Gilbert H. Kliman, MD
Managing Director
InterWest Partners
Trends in Private Company Financing
& Exits in Ophthalmology
Jonathan Norris, Managing Director
Silicon Valley Bank
Public Market Trends
in Ophthalmology
Andrew Gitkin, Head, West Coast Investment Banking
Piper Jaffray

16. Innovation in Retinal Imaging: Opportunities & Challenges
Presentations
Introduced By:
William J. Link, PhD
Managing Director
Versant Ventures
History of OCT-A
David Huang, MD, PhD
History of Intraoperative OCT
Cynthia Toth, MD

17. Innovation in Retinal Imaging: Opportunities & Challenges
Panel Discussion
Moderated By:
William J. Link, PhD
Managing Director
Versant Ventures
Participants:
Ralf Kuschnereit, PhD, SVP
Ophthalmic Systems Division
Carl Zeiss Meditec AG
Kester Nahen, PhD
Managing Director
Heidelberg Engineering
Heinrich Dreyer, PhD
VP, Medical Division
Leica Microsystems
Ryan Bouchard
Director, Medical Devices
Ora

18. Paying for Breakthrough Eye Therapies
(Biologics, Biosimilars & Gene Therapies)
Company Presentations
Moderated By:
Tarek Hassan, MD

19. Paying for Breakthrough Eye Therapies
(Biologics, Biosimilars & Gene Therapies)
Panel Discussion
Participants:
Trex Topping, MD John Thompson, MD
Jay Duker, MD Joshua Schimmer, MD
Senior Research Analyst
Piper Jaffray
Co-Moderated By:
Tarek Hassan, MD
Gilbert H. Kliman, MD
Managing Director
InterWest Partners

20. Emerging Approaches to Combination Therapies in AMD & DME
Company Presentations
Moderated By:
Mark Humayun, MD, PhD

21. Emerging Approaches to Combination Therapies in AMD & DME
Panel Discussion
Participants:
Pravin Dugel, MD Donald J. D’Amico, MD
Mark Blumenkranz, MD Adnan Butt
Biotech Analyst
RBC Capital Markets
Co-Moderated By:
Mark Humayun, MD, PhD
Emmett T. Cunningham Jr.,
MD, PhD, MPH
Partner
Clarus
Peter Kaiser, MD

22. Masters of the Industry
Moderated By:
Jim Mazzo
Global President of Ophthalmology
Carl Zeiss Meditec
Participants:
Ludwin Monz, PhD
President & CEO
Carl Zeiss Meditec AG
Tony Adamis, MD
Global Head, I2O & Metabolism,
Clinical Science
Genentech
Frederic Guerard
Worldwide Business Franchise Head,
Ophthalmology
Novartis
William J. Link, PhD
Managing Director
Versant Ventures

23. Networking Reception Host